Cladribine

FDA Drug Profile — Cladribine, Mavenclad

Cladribine is listed in the FDA National Drug Code directory with 19 NDC codes, marketed under brand names including Cladribine, Mavenclad. Available dosage forms: powder, tablet, injection, solution, injection.

Drug details

Generic Name
Cladribine
Brand Names
Cladribine, Mavenclad
Application Number
ANDA218425
Sponsor
Reliable Biopharmaceutical LLC
NDC Codes
19
Dosage Forms
POWDER, TABLET, INJECTION, SOLUTION, INJECTION
Routes
ORAL, INTRAVENOUS
Active Ingredients
CLADRIBINE

Indications and Usage

1 INDICATIONS AND USAGE Cladribine is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of cladribine is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS [see Warnings and Precautions (5) ]. Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of cladribine is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS. ( 1 , 5 ) Limitations of Use Cladribine is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile . ( 1 , 5 ) Limitations of Use Cladribine is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile [see Warnings and Precautions (5) ].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.